US 8,209,013 B2Grant
Therapeutic electrical stimulation that avoids undesirable activation
Issue Date:2012-06-26
•10 Claims
•8 Drawing Sheets
Abstract
Energy parameters for electrical stimulation pulses that produce a desired activation, and avoid an undesirable activation, are determined. A strength-duration relationship for at least one desired activation produced by therapeutic electrical stimulation is measured. A strength-duration relationship for at least one undesirable activation produced by the therapeutic electrical stimulation is provided. A medical device selects, based on the desired and undesirable strength-duration relationships, one or more energy parameters for the therapeutic electrical stimulation that produce the desired activation and avoid the undesirable activation.
Metadata
Assignee
- Cardiac Pacemakers, Inc.
Inventors
- M. Jason Brooke
- Alok S. Sathaye
- Yanting Dong
- Scott Walczak
Application Information
Application Number:US 11/520,879
Filing Date:2006-09-14
Priority Date:2006-09-14
Art Unit:3766
Classifications
IPC:
A61N1/362
Patent Drawings (8 sheets)
Description
Field of the Invention
[0001] The present invention relates generally to methods and devices for determining energy parameters for therapeutic electrical stimulation that produce a desired activation and avoid an undesirable activation.
Background of the Invention
[0002] When functioning normally, the heart produces rhythmic contractions and is capable of pumping blood throughout the body. The heart has specialized conduction pathways in both the atria and the ventricles that enable excitation impulses (i.e. depolarizations) initiated from the sino-atrial (SA) node to be rapidly conducted throughout the myocardium. These specialized conduction pathways conduct the depolarizations from the SA node to the atrial myocardium, to the atrio-ventricular node, and to the ventricular myocardium to produce a coordinated contraction of both atria and both ventricles.
[0003] The conduction pathways synchronize the contractions of the muscle fibers of each chamber as well as the contraction of each atrium or ventricle with the opposite atrium or ventricle. Without the synchronization afforded by the normally functioning specialized conduction pathways, the heart's pumping efficiency is greatly diminished. Patients who exhibit pathology of these conduction pathways can suffer compromised cardiac output.
[0004] Cardiac rhythm management (CRM) devices have been developed that provide pacing stimulation to one or more heart chambers in an attempt to improve the rhythm and coordination of atrial and/or ventricular contractions. Cardiac rhythm management devices typically include circuitry to sense signals from the heart and a pulse generator for providing electrical stimulation to the heart. Leads extending into the patient's heart chamber and/or into veins of the heart and/or attached to the heart are coupled to electrodes that sense the heart's electrical signals and deliver stimulation to the heart in accordance with various therapies for treating cardiac arrhythmias and dysynchronies.
[0005] Pacemakers are CRM devices that deliver a series of low energy pace pulses timed to assist the heart in producing a contractile rhythm that maintains cardiac pumping efficiency. Pace pulses may be intermittent or continuous, depending on the needs of the patient. There exist a number of categories of pacemaker devices, with various modes for sensing and pacing one or more heart chambers.
[0006] A pace pulse must exceed a minimum energy value, or capture threshold, to “capture” the heart tissue by generating a propagating depolarization wave that results in a contraction of the heart chamber. It is desirable for a pace pulse to have sufficient energy to capture the heart chamber without expending energy significantly in excess of the capture threshold.
[0007] If the pace pulse energy is too low, the pace pulses may not reliably produce a contractile response in the heart chamber, resulting in ineffective pacing. If the pace pulse energy is too high, the pacing pulses produce capture, but may also inadvertently stimulate the heart in an undesirable mode or may undesirably stimulate other body structures. The present invention provides an approach for determining energy parameters for cardiac pacing and/or other therapeutic electrical stimulation that produces a desired activation, such as capture, and avoids undesirable activation.
Summary of the Invention
[0008] The present invention involves approaches for determining the energy for therapeutic electrical stimulation that avoids undesirable activation. One embodiment of the invention is directed to a method implementable in a medical device for determining energy parameters for a therapeutic electrical stimulation. A strength-duration relationship for at least one desired activation produced by the therapeutic electrical stimulation is measured. A strength-duration relationship for at least one undesirable activation produced by the therapeutic electrical stimulation is provided. The medical device selects, based on the desired and undesirable strength-duration relationships, one or more energy parameters for the therapeutic electrical stimulation that produce the desired activation and avoid the undesirable activation.
[0009] For example, the strength-duration relationship for the desired activation may comprise a strength-duration relationship for capture of a heart by pacing pulses delivered to the heart. Measuring the strength-duration relationship for the desired activation may involve automatically measuring the strength-duration relationship for capture. In one approach, providing the strength-duration relationship for the undesirable activation may involve providing an amplitude threshold for undesirable activation. In another approach, the strength-duration relationship for undesirable activation may be provided by measuring the strength-duration relationship for the undesirable activation for a particular patient. In a further approach, the strength-duration relationship for undesirable activation may be determined based on theoretical analysis. In yet another approach, the strength-duration curve for the undesirable activation may be determined based on population data.
[0010] The strength-duration relationship for the desired activation and/or the undesirable activation may comprise multiple-point strength-duration curves. The energy parameters may be selected from a region between the desired activation strength-duration curve and the undesirable activation strength-duration curve.
[0011] In one scenario, the desired activation may comprise capture and the undesirable activation may comprise nerve activation, e.g., phrenic nerve activation, and/or skeletal muscle activation. In another scenario, the desired activation may involve cardiac capture at a cathodal pacing site and the undesirable activation may involve cardiac capture at an anodal pacing site.
[0012] According to one implementation, the strength-duration relationship for the desired activation is determined by performing a test to determine a capture amplitude threshold for cardiac pacing. An amplitude threshold for the undesirable activation is provided. The capture amplitude threshold is compared during a capture threshold test to the undesirable activation threshold. One or more test energy parameters, such as stimulation pulse width and/or stimulation pulse amplitude, are modified based on the comparison. The energy parameters for the therapeutic electrical stimulation are selected based on the modified test energy parameters.
[0013] According to one implementation, the amplitude of the test stimulation pulse may be set to the amplitude threshold of undesirable activation or the amplitude threshold of undesirable activation adjusted by a predetermined margin.
[0014] In some embodiments, an alert may be generated if the selected energy parameters for the therapeutic electrical stimulation exceed the strength-duration relationship for undesirable activation.
[0015] Another embodiment of the invention involves a therapy device which may be an implantable device. The therapy device includes electrodes configured to deliver therapeutic electrical stimulation. Device circuitry measures a strength-duration relationship for at least one desired activation. A therapy control processor configured to select, based on the strength-duration relationship for the desired activation and a strength-duration relationship for at least one undesirable activation, energy parameters for the therapeutic electrical stimulation that produces the desired activation and avoids the undesirable activation.
[0016] According to one implementation, the electrodes of the device are electrically coupled to a heart and the therapeutic electrical stimulation involves pacing pulses delivered to the heart. Capture circuitry is configured to measure the strength-duration relationship for capture of the heart. The therapy control processor selects, based on the strength-duration relationship for capture and the strength-duration relationship for the undesirable activation, energy parameters for the pacing pulses that produce capture of the heart and avoid undesirable activation.
[0017] For example, the therapy control processor may select the energy parameters for the therapeutic electrical stimulation based on a region defined by the strength-duration curve for the desired activation and the strength-duration curve for the undesirable activation.
[0018] The strength-duration relationship of the desired activation may comprise a cardiac capture amplitude threshold which is measured by measurement circuitry during a capture threshold test. The therapy processor compares the capture amplitude threshold determined by the test to an undesirable activation amplitude threshold. At least one test energy parameter is modified based on the comparison.
[0019] The above summary of the present invention is not intended to describe each embodiment or every implementation of the present invention. Advantages and attainments, together with a more complete understanding of the invention, will become apparent and appreciated by referring to the following detailed description and claims taken in conjunction with the accompanying drawings.
Brief Description of the Drawings
[0020] FIG. 1A is a block diagram of a system for selecting energy parameters for therapeutic electrical stimulation in accordance with embodiments of the invention;
[0021] FIG. 1B is a graph illustrating various aspects of a strength-duration plot for a desired activation and a strength-duration plot for an undesirable activation that may be used to determine energy parameters for a therapeutic electrical stimulation in accordance with embodiments of the invention;
[0022] FIG. 2 is a flow chart illustrating a method for determining the energy parameters for therapeutic electrical stimulation in accordance with embodiments of the invention;
[0023] FIG. 3 illustrates a therapy device that includes circuitry capable of measuring energy parameters that produce a desired activation while avoiding undesirable activation in accordance with embodiments of the invention;
[0024] FIG. 4 is a block diagram of a device for determining energy parameters for therapeutic electrical stimulation in accordance with embodiments of the invention; and
[0025] FIGS. 5 and 6 are flow charts illustrating methods for determining cardiac pacing energy parameters in accordance with embodiments of the invention.
[0026] While the invention is amenable to various modifications and alternative forms, specifics thereof have been shown by way of example in the drawings and will be described in detail below. It is to be understood, however, that the intention is not to limit the invention to the particular embodiments described. On the contrary, the invention is intended to cover all modifications, equivalents, and alternatives falling within the scope of the invention as defined by the appended claims.
Detailed Description of Various Embodiments
[0027] In the following description of the illustrated embodiments, references are made to the accompanying drawings forming a part hereof, and in which are shown by way of illustration, various embodiments by which the invention may be practiced. It is to be understood that other embodiments may be utilized, and structural and functional changes may be made without departing from the scope of the present invention.
[0028] Systems, devices or methods according to the present invention may include one or more of the features, structures, methods, or combinations thereof described herein. For example, a device or system may be implemented to include one or more of the advantageous features and/or processes described below. It is intended that such device or system need not include all of the features described herein, but may be implemented to include selected features that provide for useful structures and/or functionality. Such a device or system may be implemented to provide a variety of therapeutic or diagnostic functions.
[0029] Implantable devices have been used to deliver therapeutic electrical stimulation to treat patients suffering from various disorders. For example, electrical stimulation of the hypoglossal nerve has been used as therapy for sleep apnea, electrical stimulation of baroreceptors has been used as therapy for hypertension, electrical stimulation of the vagal nerve has been suggested for treatment of depression, obesity, and epilepsy. In addition, electrical stimulation of the heart has been used to provide therapy for anomalies of cardiac rhythm or synchronization.
[0030] Methods and devices described herein are directed to an approach for selecting energy parameters for the delivery of therapeutic electrical stimulation. Electrical stimulation delivered to one body structure to produce a desired therapeutic activation may undesirably cause activation of another body structure. According to various embodiments, appropriate selection of the energy parameters that produce the desired activation and avoid the undesirable activation involves the use of strength-duration relationships measured or otherwise provided for the desired activation and the undesirable activation. According to various aspects of the invention, the selection of energy parameters may involve selection of one or more of pulse width, pulse amplitude, frequency, duty cycle, pulse geometry, and/or other energy parameters. Some embodiments provided herein are described within the context of selecting the energy parameters pulse amplitude and pulse width for cardiac pacing. However, it will be appreciated that the techniques for selecting energy parameters in accordance with these examples may be extended to any of type of energy parameter, any type of therapeutic electrical stimulation, and/or any type of undesirable activation.
[0031] For example, in one implementation, the desired activation involves cardiac capture and the undesirable activation involves nerve and/or muscle activation. In another implementation, the desired activation involves nerve activation and the undesirable activation involves muscle activation. Various other combinations of desired and undesirable activations are considered to be within the scope of the present invention.
[0032] FIG. 1A depicts a block diagram of a system 100 that may be used to determine the energy parameters, i.e., strength and duration, of electrical stimulation pulses for therapeutic stimulation in accordance with embodiments of the invention. The system includes circuitry 101 configured to measure the strength-duration relationship for at least one desirable activation. For example, the circuitry 101 may automatically or semi-automatically perform a test to determine strength-duration parameters of electrical stimulation pulses that produce a desired activation. The strength-duration relationship so measured may comprise one point or multiple points of the desired activation strength-duration relationship. One example of a desirable activation comprises cardiac capture, although activation of various nerves and muscles by electrical stimulation has been used for various therapeutic purposes. For example, activation of the hypoglossal nerve has been used as a treatment for sleep apnea as described in U.S. Pat. No. 5,591,216 which is incorporated herein by reference. Electrical activation of baroreceptors has been used for treatment of hypertension and/or to reduce myocardial ischemic damage as described in commonly owned U.S. Patent Publication 20050143785 which is incorporated herein by reference.
[0033] The system 100 includes circuitry 102 configured to measure or otherwise provide the strength-duration relationship for one or more undesirable activations. The strength and duration parameters of electrical stimulation that causes undesirable stimulation may be provided by various methods. In one example, the circuitry 102 may involve communication circuitry having a user interface configured to input strength and duration parameters for undesirable activation from an external device. In another example, the circuitry 102 may be configured to measure the strength and/or duration of electrical stimulation pulses that produce the undesirable stimulation.
[0034] In various implementations, the undesirable activation may comprise skeletal muscle activation, undesirable modes of cardiac activation, and/or undesirable nerve activation. Commonly owned U.S. Pat. No. 6,772,008, which is incorporated herein by reference, describes methods and systems that may be used in relation to measuring undesirable skeletal muscle activation. Skeletal muscle activation may be measured, for example, through the use of an accelerometer and/or other circuitry that senses accelerations indicating muscle movements that coincide with the output of the stimulation pulse.
[0035] Other methods of measuring skeletal muscle activation may involve, for example, the use of an electromyogram sensor (EMG), microphone, and/or other sensors. In one implementation, activation of the laryngeal muscles may be automatically detected using a microphone to detect the patient's coughing response to undesirable activation of the laryngeal muscles due to electrical stimulation. A relationship between the coughing response and the energy parameters of electrical stimulation may be determined during a test which can be performed on command or automatically by the measurement circuitry 102.
[0036] In another implementation, the relationship between the coughing response and laryngeal muscle activation may be detected by a listener who assists in determining the strength-duration relationship of the undesirable stimulation during a test. The strength-duration relationship determined with the assistance of the listener may be input to the system via input circuitry 102 coupled to the control processor 103.
[0037] Undesirable nerve activation may be detected by sensing a parameter that is directly or indirectly responsive to the nerve activation. Undesirable nerve activation, such as activation of the vagus or phrenic nerves, for example, may be directly sensed using electroneurogram (ENG) electrodes and circuitry to measure and/or record nerve spikes and/or action potentials in a nerve. An ENG sensor may comprise a neural cuff and/or other type or neural electrodes located on or near the nerve of interest. For example, systems and methods for direct measurement of nerve activation signals are discussed in U.S. Pat. Nos. 4,573,481 and 5,658,318 which are incorporated herein by reference. The ENG may comprise a helical neural electrode that wraps around the nerve and is electrically connected to circuitry configured to measure the nerve activity. The neural electrodes and circuitry operate to detect an electrical activation (action potential) of the nerve following application of the electrical stimulation pulse.
[0038] In another approach, neural activation is detected by sensing a surrogate parameter that is indirectly responsive to nerve stimulation. Blood pressure and heart rate are two examples of parameters that change responsive to stimulation of the vagus nerve. In some embodiments, a patient's blood pressure and/or heart rate may be measured during and/or closely following delivery of electrical stimulation. The detected change in blood pressure and/or heart rate may be related to activation of the vagus nerve.
[0039] Values from the desirable activation measurement circuitry 101 and the undesirable activation circuitry 102 are provided to a control processor 103. The control processor 103 determines, from the strength-duration relationship of the desirable activation and the strength-duration relationship of the undesirable activation, the energy parameters for therapeutic electrical stimulation pulses. Control signals developed by the control processor 103 may be used to control electrical stimulation pulses produced by a therapy device 105 and delivered to a patient.
[0040] Cardiac rhythm management (CRM) devices typically include multiple pacing electrodes disposed in, on, or about the heart. For example, the electrodes may be disposed within or on a single heart chamber and/or within or on multiple heart chambers. In bipolar pacing of a heart chamber, electrodes used for delivery of pacing pulses include one or more cathode electrodes and one or more anode electrodes disposed within or on the heart chamber. Typically, pacing energy is delivered to the heart tissue via the cathode electrode(s) with a return path provided via the anode electrode(s). If capture occurs, the energy injected at the cathode electrode site creates a propagating wavefront of depolarization that triggers a contraction of the cardiac muscle.
[0041] Undesirable cardiac stimulation modes and/or stimulation of extra-cardiac structures constrains the energy level used for pacing pulses. For example, pacing at excessive energy levels may cause the cardiac tissue to be stimulated at the site of the anode electrode instead of the cathode electrode as expected. Cardiac signals sensed following the pacing pulse are analyzed to determine if a pacing pulse captured the cardiac tissue. Capture via anodal activation may result in erroneous detection of capture or loss of capture.
[0042] In some scenarios, excessive pacing levels may cause undesirable activation of extracardiac nerve or muscle tissues. For example, left ventricular pacing at energy levels exceeding a threshold level may cause undesirable activation of the diaphragm and/or phrenic nerve.
[0043] Capture is produced by pacing pulses having sufficient energy to produce a propagating wavefront of electrical depolarization that results in a contraction of the heart tissue. The energy of the pacing pulse is a product of two energy parameters the amplitude of the pacing pulse and the duration of the pulse. Thus, the capture threshold voltage over a range of pulse widths may be expressed in a strength-duration plot 110 as illustrated in FIG. 1B . A CRM device, such as a pacemaker, may have the capability to adjust the pacing pulse energy by modifying either or both the pulse energy and the pulse amplitude to produce capture.
[0044] Undesirable activation by a pacing pulse is also dependent on the pulse energy. The strength-duration plot 120 for undesirable activation may have a different characteristic from the capture strength-duration and may have a relationship between pacing pulse voltage and pacing pulse width.
[0045] FIG. 1B provides graphs illustrating a strength-duration plot 110 associated with capture and a strength-duration plot 120 associated with an undesirable activation. A pacing pulse having a pulse width of W1 requires a pulse amplitude of Vc1 to produce capture. A pacing pulse having pulse width W1 and pulse amplitude Vc1 exceeds the voltage threshold, Vu1, for an undesirable activation. If the pulse width is increased to W2, the voltage required for capture, Vc2, is less than the voltage required for undesirable activation, Vu2. Therefore, pacing pulses can be delivered at the pacing energy associated with W2, Vc2 to provide capture of the heart without causing the undesirable activation. The shaded area 150 between the plots 110, 120 indicates the energy parameter values that may be used to produce capture and avoid undesirable activation.
[0046] Embodiments of the invention are directed to methods and systems for determining one or more energy parameters for therapeutic electrical stimulation, e.g., pulse width and/or pulse amplitude, for electrical stimulation delivered to a patient. FIG. 2 provides a flow chart that illustrates one method for determining the energy parameters. A strength-duration relationship for a desired activation is measured 210. A strength-duration relationship for at least one undesirable activation is provided 220. Although examples are described herein in the context of determining energy parameters that avoid one undesirable activation, extending the approaches to determine energy parameters that avoid multiple undesirable activations will be readily understandable to one skilled in the art.
[0047] The strength-duration relationship for the desired activation and/or the strength-duration relationship for undesirable activation may be provided or measured as a single threshold coordinate (W, V). Alternatively, one or more of the strength-duration relationships may be provided or measured as multiple points of the strength-duration plots. The energy parameters, e.g., pulse width and/or pulse amplitude, that produce the desired activation, e.g., capture of the heart, and avoid undesirable activation are selected 230 based on a comparison of the strength-duration relationship for the desired activation and the strength-duration relationship for undesirable activation.
[0048] In some implementations, the strength-duration relationship for capture may be determined by a CRM device. For example, testing to determine one or more points of the strength-duration relationship may be automatically performed by a CRM device periodically, upon detection of loss of capture, or triggered by receipt of a command to perform the test. The testing may determine a single point, (W, V), of the strength-duration relationship for capture or may comprise multiple points (Wi, Vi)={(W1, V1), (W2, V2), . . . }. The strength-duration relationships for one or more types of undesirable activation may be provided or determined as single points of their respective strength-duration plots or may be provided or determined as multiple points.
[0049] In various implementations, the strength-duration relationship for the undesirable activation may be determined by theoretical analysis, such as wave dynamics and/or cell modeling, may be determined via population data, and/or may be determined by empirical assessment specific to the patient.
[0050] Measurement of the patient-specific strength-duration relationship for undesirable stimulation may be accomplished using sensors capable of detecting the occurrence of the undesirable activation following delivery of a pacing pulse. For example, in some implementations, the undesirable activation comprises cardiac capture from the site of the anodal pacing electrode. This type of undesirable activation is referred to herein as anodal activation. Anodal activation is recognizable by a physician from an electrogram (EGM) or electrocardiogram (ECG) that has been previously collected and stored or displayed in real time. One or more points of the anodal activation strength-duration relationship may be determined by the physician from the EGM or ECG and used for selecting appropriate energy parameters for pacing. For example, the physician may determine whether or not certain test energy parameters caused anodal activation by examining the EGM or ECG. This information may then be input to a device for use as the strength-duration relationship of the undesirable activation.
[0051] If multiple-point strength duration plots are known for both capture and the undesirable activation, the energy parameters may be determined based on these two plots. For example, returning to FIG. 1B , the area 150 to the right of the intersection 151 of the strength-duration plots 110, 120 defines the set of energy parameter values that produce capture while avoiding the undesirable stimulation. Energy parameter values that fall within this region 150, or within a modified region 160 that includes appropriate safety margins for pacing 161 and undesirable activation 162, may be selected. In one implementation of the process, the energy parameter values may be automatically selected by the CRM device.
[0052] In another implementation of the process, information related to the strength-duration relationships measured for capture and for undesirable activation may be transmitted from the CRM device to a patient-external device, such as a device programmer, advanced patient management system, or other external device. The strength-duration curves may be displayed on a display device for viewing by a physician, such as in an overlaid graph similar to FIG. 1B . Based on the displayed information, the physician may select a voltage threshold value for undesirable activation. For example, the physician may select a voltage threshold value, VuT, shown in FIG. 1B . The undesirable activation threshold voltage, VuT, may be used to constrain the pacing voltage to a value that will avoid undesirable activation.
[0053] The therapy device 300 illustrated in FIG. 3 employs circuitry capable of implementing the techniques described herein for determining energy parameters that produce capture while avoiding undesirable activation. The therapy device 300 includes cardiac rhythm management (CRM) circuitry enclosed within an implantable housing 301. The CRM circuitry is electrically coupled to an intracardiac lead system 310.
[0054] Portions of the intracardiac lead system 310 are inserted into the patient's heart. The lead system 310 includes cardiac pace/sense electrodes 351-356 positioned in, on, or about one or more heart chambers for sensing electrical signals from the patient's heart and/or delivering pacing pulses to the heart. The intracardiac sense/pace electrodes 351-356, such as those illustrated in FIG. 3 , may be used to sense and/or pace one or more chambers of the heart, including the left ventricle, the right ventricle, the left atrium and/or the right atrium. A therapy control processor controls the delivery of pacing pulses delivered via the electrodes 351-356.
[0055] Bipolar electrical stimulation pulses may be delivered via two of the electrodes 351-356. For example, bipolar pacing of the right ventricle may be delivered via electrodes 353 and 356 with the distal tip electrode 353 as the cathode and the proximal ring electrode as the anode. Bipolar pacing of the left ventricle may be delivered via distal and proximal electrodes 355, 354. Bipolar pacing of the right atrium via may be delivered via distal tip 352 and proximal ring 351 electrodes.
[0056] Unipolar pacing may be delivered to a heart chamber, for example, using the can 381 and/or indifferent electrode 382 in conjunction with an electrode positioned within or on the paced heart chamber, such as the right ventricular distal tip electrode 353 for right ventricular pacing, the left ventricular distal electrode 355 for left ventricular pacing, or the right atrial distal tip electrode 352 for right atrial pacing. The electrical stimulation pulses delivered to the heart chamber may be used to ensure that the heart beats at a hemodynamically sufficient rate, may be used to improve the synchrony of the heart beats, may be used to increase the strength of the heart beats, and/or may be used for other therapeutic purposes.
[0057] The lead system 310 includes defibrillation electrodes 341, 342 for delivering defibrillation/cardioversion shocks to the heart. Electrode/lead configurations other than those illustrated in FIG. 3 may alternatively or additionally used. For example, the electrodes of the CRM device may include epicardial electrodes, subcutaneous electrodes, and or other electrode types.
[0058] The left ventricular lead 305 incorporates electrodes 354 and 355 positioned at various locations within the coronary venous system proximate the left ventricle. Stimulating the ventricle at multiple locations in the left ventricle or at a single selected location may provide for increased cardiac output in a patients suffering from congestive heart failure (CHF), for example, and/or may provide for other benefits. Biventricular stimulation pulses may be delivered via electrodes in the left, right or both ventricles according to a phased timing sequence and output configuration that enhances cardiac function.
[0059] Portions of the housing 301 of the implantable device 300 may optionally serve as one or multiple can or indifferent electrodes 381, 382. The housing 301 is illustrated as incorporating a header 389 that may be configured to facilitate removable attachment between one or more leads and the housing 301. The housing 301 of the therapy device 300 may include one or more can electrodes 381. The header 389 of the therapy device 300 may include one or more indifferent electrodes 382. The indifferent and/or can electrodes may be used to deliver unipolar pacing or defibrillation/cardioversion.
[0060] Communications circuitry is disposed within the housing 301 for facilitating communication between the CRM circuitry and a patient-external device, such as an external programmer or advanced patient management (APM) system. The therapy device 300 may also include sensors and appropriate circuitry for sensing a patient's metabolic need and adjusting the pacing pulses delivered to the heart to accommodate the patient's metabolic need.
[0061] In certain embodiments, the therapy device 300 may include circuitry for detecting and treating cardiac tachyarrhythmia via defibrillation therapy and/or anti-tachyarrhythmia pacing (ATP). Configurations providing defibrillation capability may make use of defibrillation coils 341, 342 for delivering high energy shocks to the heart to terminate or mitigate tachyarrhythmia.
[0062] FIG. 4 is a block diagram of a CRM device 400 that incorporates circuitry for determining energy parameters in accordance with embodiments of the invention. The CRM device 400 includes pacing therapy circuitry 430 capable of detecting arrhythmias and controlling the delivery pacing pulses and/or other forms of electrical stimulation to treat the arrhythmias. The CRM device 400 includes pacing circuitry for treating bradyarrhythmia and may optionally include defibrillation/cardioversion circuitry 435 configured to deliver high energy defibrillation or cardioversion stimulation to the heart for terminating dangerous tachyarrhythmias.
[0063] The pacing and/or defibrillation pulses are delivered via multiple cardiac electrodes 405 electrically coupled to a heart disposed at multiple locations within, on, or about the heart. One or more electrodes may be disposed within each heart chamber. The electrodes 405 are coupled to switch matrix 425 circuitry used to selectively couple electrodes 405 to capture measurement circuitry 415, optional undesirable activation measurement circuitry 420, and/or other components of the CRM device 400, via sense/detection circuitry 410 as shown. The capture measurement circuitry 415 may be configured to measure the capture strength-duration relationship or capture threshold (W, V), for example, by periodically initiating step-up, step-down, binary search, or other types of capture threshold tests. The capture measurement circuitry 415, in conjunction with other components of the CRM device 400, may be configured to perform measurements to determine single-point capture thresholds and/or may be configured to determine and store a multiple-point strength-duration relationships for capture of one or more heart chambers.
[0064] Optionally, in one configuration, the CRM device 400 includes undesirable activation measurement circuitry 420. The undesirable activation measurement circuitry 420, if used, may be configured to measure one or more points of the strength-duration relationships for one or more undesirable activations.
[0065] In another configuration, one or more points of a strength-duration curve for an undesirable activation may be transmitted to the CRM device 400 via a patient-external device 455, such as a programmer, advanced patient management server, or other device, via communications circuitry 450.
[0066] The strength-duration relationship values, whether measured from the patient, or received via the external device, are used by the therapy control processor 440 to select energy parameters for pacing that provide for capture of the heart while avoiding undesirable stimulation. The therapy control processor may perform capture tests, for example, periodically, if loss of capture is detected, or on command, to determine the pacing energy parameters that produce capture and avoid undesirable activation. If the testing fails to identify pacing energy parameters that produce capture and avoid undesirable activation, the therapy control processor 440 may generate an alert that can be communicated to the external device 455 via the communication circuitry 450.
[0067] In addition to using the strength-duration relationships for setting pacing energy parameter values, the values obtained during repeated strength-duration measurements may be stored in memory 445 along with the selected pacing energy parameters. The stored strength-duration relationships and/or pacing energy parameters may be downloaded to an external device 455 periodically or on command via the communications circuitry 450. The strength-duration plots and/or selected energy parameters can be displayed on the external device or may be used to generate a report accessible to a physician, certified professional, and/or advanced patient management system. The information may be used to track changes over time in the strength-duration plots and/or selected energy parameters.
[0068] FIG. 5 is a flow chart of a method for determining pacing energy parameters in accordance with one embodiment. In this implementation, prior to the start 510 of a test to determine the pacing amplitude and pulse width, a undesirable activation pulse amplitude threshold has been determined by the device, or otherwise provided. The undesirable activation threshold may be a fixed value across all patients, may be provided for the particular patient from population data or theoretical analysis, or may be determined from measurements made by the CRM device as previously discussed.
[0069] The amplitude for the pacing pulse is set 515 to a beginning pace amplitude, such as the amplitude value previously used for pacing plus a margin, where the margin may be a fixed or programmable value. For example, beginning pace amplitude may ensure that the pacing energy exceeds the capture threshold and/or exceeds the undesirable activation threshold. The pulse width for the pacing pulse may also be set 520 to a predetermined value, such as the previous pulse width threshold value. A capture threshold test sequence is performed 525, which may involve a step-up, step-down, binary search, or other type capture threshold measurement for determining 530 the pulse amplitude threshold for capture.
[0070] If the pulse amplitude for capture determined by the capture threshold test is greater than 535 the threshold value for the undesirable activation, the pulse amplitude and/or width may be modified and the test repeated. The decision that modifies the pacing energy parameters may involve various methods for determining how to set the pacing energy parameters. In various implementations, the pulse amplitude and/or pulse width may be modified during the capture threshold test based on the strength-duration relationship for undesirable activation and/or a strength-duration relationship for capture. The determination and use of patient-specific strength-duration relationships promotes selection of optimal, patient-specific pacing energy parameters while improving testing efficiency and minimizing testing to determine pacing energy parameters.
[0071] In one particular implementation, the pulse amplitude is set 540 to the test starting value, or to another predetermined value, such as the undesirable stimulation amplitude threshold value. The pulse width is increased 545 and the test is repeated 525. The process 525-545 is repeated until the pulse amplitude for capture is less than 535 the pulse amplitude threshold for the undesirable stimulation.
[0072] If the pulse amplitude for capture is less than 535 the pulse amplitude threshold for the undesirable stimulation, the test mode is exited, see block 550. The pacing pulse amplitude is programmed 555 to the capture threshold value returned by the capture threshold test plus a safety margin. The pacing pulse width is programmed 560 to the value returned by the capture threshold test.
[0073] FIG. 6 is a flow chart of another method for performing a capture test to determine pacing energy parameters in accordance with one embodiment. As before, in this implementation, prior to the start 610 of the test, a undesirable activation pulse amplitude threshold has been determined by the device, or otherwise provided. The amplitude for the pacing pulse is set 615 to a beginning pace amplitude, such as the previous threshold amplitude value plus a fixed or programmable margin as previously discussed. The pulse width for the pacing pulse may also be set 620 to a predetermined value, such as the previous pulse width threshold value.
[0074] The capture threshold test sequence is performed 625, which may involve a step-up, step-down, binary search, or other type capture threshold measurement for determining 630 the pulse amplitude threshold for capture.
[0075] If the pulse amplitude for capture determined by the capture threshold test is less than 635 the threshold value for the undesirable activation, the process exits 650 the test mode. If the pulse amplitude for capture is greater than 635 the threshold value for the undesirable activation, the pulse amplitude and/or pulse width is modified. In various implementations, the pulse amplitude and/or pulse width may be modified during the capture threshold test based on the strength-duration relationship for undesirable activation and/or a strength-duration relationship for capture. In one particular implementation, the pulse amplitude is set 640 to the undesirable stimulation threshold value minus a safety margin. The pulse width is incrementally increased 645 until capture is detected 665.
[0076] When capture is detected 665, the test mode is exited 650. The pacing pulse amplitude is programmed 655 to the value returned by the capture threshold test plus a safety margin. The pacing pulse width is programmed 660 to the value returned by the capture threshold test.
[0077] The embodiments of the invention described herein may be used in conjunction with any type of therapeutic device in which stimulation thresholds are used to provide for appropriate energy parameter settings, including cardiac and neurological stimulation devices. The flexibility and automaticity of the approach allow for use in implanted devices where manual and/or automatic energy parameter selection may be implemented. Use of the methods and systems described herein may be used to provide for enhanced patient safety and comfort as well as therapy effectiveness. Use of patient-specific strength-duration relationships allows safety, efficacy and optimization of therapy individually for each patient. The approaches described herein may be used along with remote follow-up or patient management systems for providing additional data that may be used to inform physician decisions regarding the titration of therapy.
[0078] The components, functionality, and structural configurations depicted herein are intended to provide an understanding of various features and combination of features that may be incorporated in an implantable pacemaker/defibrillator. It is understood that a wide variety of cardiac monitoring and/or stimulation device configurations are contemplated, ranging from relatively sophisticated to relatively simple designs. As such, particular cardiac device configurations may include particular features as described herein, while other such device configurations may exclude particular features described herein.
[0079] Various modifications and additions can be made to the preferred embodiments discussed hereinabove without departing from the scope of the present invention. Accordingly, the scope of the present invention should not be limited by the particular embodiments described above, but should be defined only by the claims set forth below and equivalents thereof.
Claims
What is claimed is:
1. A therapy device, comprising:
electrodes configured to deliver therapeutic electrical stimulation;
measurement circuitry configured to measure a capture threshold during a capture threshold test, to modify at least one capture threshold test energy parameter based on a strength-duration relationship for at least one undesirable nerve or muscle activation, to perform an additional capture threshold test to determine an additional capture threshold using the modified test energy parameter, and to determine energy parameters for the therapeutic electrical stimulation that produce capture and avoid the undesirable nerve or muscle activation using the additional capture threshold; and
a therapy control processor configured to use the energy parameters for delivery of the therapeutic electrical stimulation;
wherein the modified test energy parameter comprises a pulse amplitude set to an undesirable nerve or muscle activation threshold which is based on the strength-duration relationship for the undesirable nerve or muscle activation.
2. A device of claim 1, wherein:
the electrodes are electrically coupled to a heart;
the therapeutic electrical stimulation comprises pacing pulses to the heart; and
the measurement circuitry comprises circuitry configured to measure the strength-duration relationship of the undesirable activation.
3. The device of claim 1, wherein:
the strength-duration relationship for undesirable activation comprises a multiple-point strength-duration curve for undesirable activation.
4. The device of claim 1, wherein the undesirable activation comprises activation of a phrenic nerve.
5. The device of claim 1, wherein the undesirable activation comprises muscle activation.
6. The device of claim 1, wherein the at least one modified test energy parameter comprises a pulse width.
7. The device of claim 1, wherein the at least one modified test energy parameter comprises a pulse amplitude.
8. The device of claim 1, wherein the measurement circuitry is configured to determine a desired activation strength-duration curve based on pulses of delivered therapeutic electrical stimulation that produced the desired activation, and the measurement circuitry is configured to determine the undesirable activation strength-duration curve based on multiple pulses of delivered therapeutic electrical stimulation that produced the undesirable activation.
9. The device of claim 1, wherein the strength-duration relationship for undesirable activation is based on population data.
10. The therapy device of claim 1, wherein the measurement circuitry is configured to perform the additional capture threshold test by increasing a pulse width until capture is detected.
Patent Citations (500)
| Patent | Date | Inventor | Cited By |
|---|---|---|---|
| US3920005(A) | 1975-11-01 | Gombrich et al. | Applicant |
| US4023564(A) | 1977-05-01 | Valiquette et al. | Applicant |
| US4340063(A) | 1982-07-01 | Maurer | Examiner |
| US4364396(A) | 1982-12-01 | Barthel | Applicant |
| US4365636(A) | 1982-12-01 | Barker | Applicant |
| US4458692(A) | 1984-07-01 | Simson | Applicant |
| US4476869(A) | 1984-10-01 | Bihn | Applicant |
| US4550221(A) | 1985-10-01 | Mabusth | Applicant |
| US4552154(A) | 1985-11-01 | Hartlaub | Applicant |
| US4562841(A) | 1986-01-01 | Brockway et al. | Applicant |
| US4573481(A) | 1986-03-01 | Bullara | Applicant |
| US4648407(A) | 1987-03-01 | Sackner | Applicant |
| US4680708(A) | 1987-07-01 | Ambos et al. | Applicant |
| US4686332(A) | 1987-08-01 | Greanias et al. | Applicant |
| US4827935(A) | 1989-05-01 | Geddes et al. | Applicant |
| US4860766(A) | 1989-08-01 | Sackner | Applicant |
| US4878497(A) | 1989-11-01 | Callaghan et al. | Applicant |
| US4928688(A) | 1990-05-01 | Mower | Applicant |
| US4953551(A) | 1990-09-01 | Mehra et al. | Applicant |
| US4979507(A) | 1990-12-01 | Heinz et al. | Examiner |
| US5000189(A) | 1991-03-01 | Throne et al. | Applicant |
| US5033467(A) | 1991-07-01 | Bocchi et al. | Applicant |
| US5036849(A) | 1991-08-01 | Hauck et al. | Applicant |
| US5101831(A) | 1992-04-01 | Koyama et al. | Applicant |
| US5105354(A) | 1992-04-01 | Nishimura | Applicant |
| US5133353(A) | 1992-07-01 | Hauser | Applicant |
| US5146918(A) | 1992-09-01 | Kallok et al. | Applicant |
| US5170784(A) | 1992-12-01 | Ramon et al. | Applicant |
| US5178156(A) | 1993-01-01 | Takishima et al. | Applicant |
| US5179945(A) | 1993-01-01 | Van Hofwegen et al. | Applicant |
| US5184615(A) | 1993-02-01 | Nappholz et al. | Applicant |
| US5187657(A) | 1993-02-01 | Forbes | Applicant |
| US5203348(A) | 1993-04-01 | Dahl et al. | Applicant |
| US5209229(A) | 1993-05-01 | Gilli | Applicant |
| US5217021(A) | 1993-06-01 | Steinhaus et al. | Applicant |
| US5222493(A) | 1993-06-01 | Sholder | Applicant |
| US5230337(A) | 1993-07-01 | Dahl et al. | Applicant |
| US5233983(A) | 1993-08-01 | Markowitz | Applicant |
| US5261400(A) | 1993-11-01 | Bardy | Applicant |
| US5271411(A) | 1993-12-01 | Ripley et al. | Applicant |
| US5273035(A) | 1993-12-01 | Markowitz et al. | Applicant |
| US5284136(A) | 1994-02-01 | Hauck et al. | Applicant |
| US5292338(A) | 1994-03-01 | Bardy | Applicant |
| US5300106(A) | 1994-04-01 | Dahl et al. | Applicant |
| US5301677(A) | 1994-04-01 | Hsung | Applicant |
| US5313953(A) | 1994-05-01 | Yomtov et al. | Applicant |
| US5314430(A) | 1994-05-01 | Bardy | Applicant |
| US5314459(A) | 1994-05-01 | Swanson et al. | Applicant |
| US5318597(A) | 1994-06-01 | Hauck et al. | Applicant |
| US5324310(A) | 1994-06-01 | Greeninger et al. | Applicant |
| US5331966(A) | 1994-07-01 | Bennett et al. | Applicant |
| US5331996(A) | 1994-07-01 | Ziehm | Applicant |
| US5333095(A) | 1994-07-01 | Stevenson et al. | Applicant |
| US5334222(A) | 1994-08-01 | Salo et al. | Applicant |
| US5335657(A) | 1994-08-01 | Terry, Jr. et al. | Applicant |
| US5350410(A) | 1994-09-01 | Kleks et al. | Applicant |
| US5353788(A) | 1994-10-01 | Miles | Applicant |
| US5360442(A) | 1994-11-01 | Dahl et al. | Applicant |
| US5366496(A) | 1994-11-01 | Dahl et al. | Applicant |
| US5372606(A) | 1994-12-01 | Lang et al. | Applicant |
| US5374280(A) | 1994-12-01 | den Dulk | Applicant |
| US5376106(A) | 1994-12-01 | Stahmann et al. | Applicant |
| US5376476(A) | 1994-12-01 | Eylon | Applicant |
| US5388578(A) | 1995-02-01 | Yomtov et al. | Applicant |
| US5391200(A) | 1995-02-01 | KenKnight et al. | Applicant |
| US5397342(A) | 1995-03-01 | Heil, Jr. et al. | Applicant |
| US5411031(A) | 1995-05-01 | Yomtov | Applicant |
| US5411525(A) | 1995-05-01 | Swanson et al. | Applicant |
| US5411529(A) | 1995-05-01 | Hudrlik | Applicant |
| US5411533(A) | 1995-05-01 | Dubreuil | Applicant |
| US5411539(A) | 1995-05-01 | Neisz | Applicant |
| US5431693(A) | 1995-07-01 | Schroeppel | Applicant |
| US5439482(A) | 1995-08-01 | Adams et al. | Applicant |
| US5441518(A) | 1995-08-01 | Adams et al. | Applicant |
| US5443485(A) | 1995-08-01 | Housworth et al. | Applicant |
| US5447519(A) | 1995-09-01 | Peterson | Applicant |
| US5468254(A) | 1995-11-01 | Hahn et al. | Applicant |
| US5485851(A) | 1996-01-01 | Erickson | Applicant |
| US5517983(A) | 1996-05-01 | Deighan et al. | Applicant |
| US5520191(A) | 1996-05-01 | Karlsson et al. | Applicant |
| US5522860(A) | 1996-06-01 | Molin et al. | Applicant |
| US5531779(A) | 1996-07-01 | Dahl et al. | Applicant |
| US5534017(A) | 1996-07-01 | Van Krieken et al. | Applicant |
| US5540727(A) | 1996-07-01 | Tockman et al. | Applicant |
| US5540732(A) | 1996-07-01 | Testerman | Applicant |
| US5545186(A) | 1996-08-01 | Olson et al. | Applicant |
| US5545202(A) | 1996-08-01 | Dahl et al. | Applicant |
| US5549655(A) | 1996-08-01 | Erickson | Applicant |
| US5591216(A) | 1997-01-01 | Testerman et al. | Applicant |
| US5603732(A) | 1997-02-01 | Dahl et al. | Applicant |
| US5620466(A) | 1997-04-01 | Haefner et al. | Applicant |
| US5626620(A) | 1997-05-01 | Kieval et al. | Applicant |
| US5634938(A) | 1997-06-01 | Swanson et al. | Applicant |
| US5641326(A) | 1997-06-01 | Adams | Applicant |
| US5650759(A) | 1997-07-01 | Hittman et al. | Applicant |
| US5658318(A) | 1997-08-01 | Stroetmann et al. | Applicant |
| US5662688(A) | 1997-09-01 | Haefner et al. | Applicant |
| US5662696(A) | 1997-09-01 | Kroll et al. | Applicant |
| US5674254(A) | 1997-10-01 | van Krieken | Applicant |
| US5683431(A) | 1997-11-01 | Wang | Applicant |
| US5683434(A) | 1997-11-01 | Archer | Applicant |
| US5697953(A) | 1997-12-01 | Kroll et al. | Applicant |
| US5697956(A) | 1997-12-01 | Bornzin | Applicant |
| US5704365(A) | 1998-01-01 | Albrecht et al. | Applicant |
| US5713933(A) | 1998-02-01 | Condie et al. | Applicant |
| US5715812(A) | 1998-02-01 | Deighan et al. | Applicant |
| US5718720(A) | 1998-02-01 | Prutchi et al. | Applicant |
| US5724984(A) | 1998-03-01 | Arnold et al. | Applicant |
| US5735883(A) | 1998-04-01 | Paul et al. | Applicant |
| US5738102(A) | 1998-04-01 | Lemelson | Applicant |
| US5779645(A) | 1998-07-01 | Olson et al. | Applicant |
| US5814087(A) | 1998-09-01 | Renirie | Applicant |
| US5817027(A) | 1998-10-01 | Arand et al. | Applicant |
| US5827326(A) | 1998-10-01 | Kroll et al. | Applicant |
| US5836987(A) | 1998-11-01 | Baumann et al. | Applicant |
| US5844506(A) | 1998-12-01 | Binstead | Applicant |
| US5855593(A) | 1999-01-01 | Olson et al. | Applicant |
| US5857977(A) | 1999-01-01 | Caswell et al. | Applicant |
| US5860918(A) | 1999-01-01 | Schradi et al. | Applicant |
| US5861011(A) | 1999-01-01 | Stoop | Applicant |
| US5861013(A) | 1999-01-01 | Peck et al. | Applicant |
| US5871512(A) | 1999-02-01 | Hemming et al. | Applicant |
| US5873898(A) | 1999-02-01 | Hemming et al. | Applicant |
| US5876353(A) | 1999-03-01 | Riff | Applicant |
| US5895414(A) | 1999-04-01 | Sanchez-Zambrano | Applicant |
| US5916243(A) | 1999-06-01 | KenKnight et al. | Applicant |
| US5944680(A) | 1999-08-01 | Christopherson et al. | Applicant |
| US5957956(A) | 1999-09-01 | Kroll et al. | Applicant |
| US5964778(A) | 1999-10-01 | Fugoso et al. | Applicant |
| US5974340(A) | 1999-10-01 | Kadhiresan | Applicant |
| US5987352(A) | 1999-11-01 | Klein et al. | Applicant |
| US6026320(A) | 2000-02-01 | Carlson et al. | Applicant |
| US6038474(A) | 2000-03-01 | Zhu et al. | Applicant |
| US6044298(A) | 2000-03-01 | Salo et al. | Applicant |
| US6045513(A) | 2000-04-01 | Stone et al. | Applicant |
| US6049730(A) | 2000-04-01 | Kristbjarnarson | Applicant |
| US6052620(A) | 2000-04-01 | Gillberg et al. | Applicant |
| US6055454(A) | 2000-04-01 | Heemels | Applicant |
| US6064910(A) | 2000-05-01 | Andersson et al. | Applicant |
| US6076014(A) | 2000-06-01 | Alt | Applicant |
| US6076015(A) | 2000-06-01 | Hartley et al. | Applicant |
| US6084253(A) | 2000-07-01 | Turner, Jr. | Applicant |
| US6091973(A) | 2000-07-01 | Colla et al. | Applicant |
| US6101416(A) | 2000-08-01 | Sloman | Applicant |
| US6115628(A) | 2000-09-01 | Stadler et al. | Applicant |
| US6120441(A) | 2000-09-01 | Griebel | Applicant |
| US6126611(A) | 2000-10-01 | Bourgeois et al. | Applicant |
| US6128534(A) | 2000-10-01 | Park et al. | Applicant |
| US6128535(A) | 2000-10-01 | Maarse | Applicant |
| US6132384(A) | 2000-10-01 | Christopherson et al. | Applicant |
| US6134473(A) | 2000-10-01 | Hemming et al. | Applicant |
| US6141581(A) | 2000-10-01 | Olson et al. | Applicant |
| US6147680(A) | 2000-11-01 | Tareev | Applicant |
| US6148230(A) | 2000-11-01 | KenKnight | Applicant |
| US6148234(A) | 2000-11-01 | Struble | Applicant |
| US6163724(A) | 2000-12-01 | Hemming et al. | Applicant |
| US6169921(B1) | 2001-01-01 | KenKnight et al. | Applicant |
| US6175766(B1) | 2001-01-01 | Bornzin et al. | Applicant |
| US6190326(B1) | 2001-02-01 | McKinnon et al. | Applicant |
| US6192275(B1) | 2001-02-01 | Zhu et al. | Applicant |
| US6221011(B1) | 2001-04-01 | Bardy | Applicant |
| US6226551(B1) | 2001-05-01 | Zhu et al. | Applicant |
| US6227072(B1) | 2001-05-01 | Ritchey et al. | Applicant |
| US6238419(B1) | 2001-05-01 | Lindgren | Applicant |
| US6251126(B1) | 2001-06-01 | Ottenhoff et al. | Applicant |
| US6253102(B1) | 2001-06-01 | Hsu et al. | Applicant |
| US6258039(B1) | 2001-07-01 | Okamoto et al. | Applicant |
| US6259947(B1) | 2001-07-01 | Olson et al. | Applicant |
| US6266554(B1) | 2001-07-01 | Hsu et al. | Applicant |
| US6270457(B1) | 2001-08-01 | Bardy | Applicant |
| US6272377(B1) | 2001-08-01 | Sweeney et al. | Applicant |
| US6275731(B1) | 2001-08-01 | Zhu et al. | Applicant |
| US6277072(B1) | 2001-08-01 | Bardy | Applicant |
| US6280380(B1) | 2001-08-01 | Bardy | Applicant |
| US6280462(B1) | 2001-08-01 | Hauser et al. | Applicant |
| US6282440(B1) | 2001-08-01 | Brodnick et al. | Applicant |
| US6285907(B1) | 2001-09-01 | Kramer et al. | Applicant |
| US6299581(B1) | 2001-10-01 | Rapoport et al. | Applicant |
| US6312378(B1) | 2001-11-01 | Bardy | Applicant |
| US6312388(B1) | 2001-11-01 | Marcovecchio et al. | Applicant |
| US6324421(B1) | 2001-11-01 | Stadler et al. | Applicant |
| US6324427(B1) | 2001-11-01 | Florio | Applicant |
| US6336903(B1) | 2002-01-01 | Bardy | Applicant |
| US6345201(B1) | 2002-02-01 | Sloman et al. | Applicant |
| US6351669(B1) | 2002-02-01 | Hartley et al. | Applicant |
| US6351673(B1) | 2002-02-01 | Ding et al. | Applicant |
| US6353759(B1) | 2002-03-01 | Hartley et al. | Applicant |
| US6358203(B2) | 2002-03-01 | Bardy | Applicant |
| US6360127(B1) | 2002-03-01 | Ding et al. | Applicant |
| US6363270(B1) | 2002-03-01 | Colla et al. | Applicant |
| US6363281(B1) | 2002-03-01 | Zhu et al. | Applicant |
| US6368284(B1) | 2002-04-01 | Bardy | Applicant |
| US6368287(B1) | 2002-04-01 | Hadas | Applicant |
| US6371922(B1) | 2002-04-01 | Baumann et al. | Applicant |
| US6375621(B1) | 2002-04-01 | Sullivan | Applicant |
| US6393316(B1) | 2002-05-01 | Gillberg et al. | Applicant |
| US6398728(B1) | 2002-06-01 | Bardy | Applicant |
| US6409675(B1) | 2002-06-01 | Turcott | Applicant |
| US6411848(B2) | 2002-06-01 | Kramer et al. | Applicant |
| US6415174(B1) | 2002-07-01 | Bebehani et al. | Applicant |
| US6415183(B1) | 2002-07-01 | Scheiner et al. | Applicant |
| US6418340(B1) | 2002-07-01 | Conley et al. | Applicant |
| US6418343(B1) | 2002-07-01 | Zhang et al. | Applicant |
| US6424234(B1) | 2002-07-01 | Stevenson | Applicant |
| US6424865(B1) | 2002-07-01 | Ding | Applicant |
| US6434417(B1) | 2002-08-01 | Lovett | Applicant |
| US6434428(B1) | 2002-08-01 | Sloman et al. | Applicant |
| US6438409(B1) | 2002-08-01 | Malik et al. | Applicant |
| US6438410(B2) | 2002-08-01 | Hsu et al. | Applicant |
| US6440066(B1) | 2002-08-01 | Bardy | Applicant |
| US6449503(B1) | 2002-09-01 | Hsu | Applicant |
| US6456481(B1) | 2002-09-01 | Stevenson | Applicant |
| US6456880(B1) | 2002-09-01 | Park et al. | Applicant |
| US6456881(B1) | 2002-09-01 | Bornzin et al. | Applicant |
| US6459929(B1) | 2002-10-01 | Hopper et al. | Applicant |
| US6466820(B1) | 2002-10-01 | Juran et al. | Applicant |
| US6477422(B1) | 2002-11-01 | Splett | Applicant |
| US6480733(B1) | 2002-11-01 | Turcott | Applicant |
| US6480734(B1) | 2002-11-01 | Zhang et al. | Applicant |
| US6487443(B2) | 2002-11-01 | Olson et al. | Applicant |
| US6491639(B1) | 2002-12-01 | Turcott | Applicant |
| US6493586(B1) | 2002-12-01 | Stahmann et al. | Applicant |
| US6496715(B1) | 2002-12-01 | Lee et al. | Applicant |
| US6505067(B1) | 2003-01-01 | Lee et al. | Applicant |
| US6505071(B1) | 2003-01-01 | Zhu et al. | Applicant |
| US6512940(B1) | 2003-01-01 | Brabec et al. | Applicant |
| US6512953(B2) | 2003-01-01 | Florio et al. | Applicant |
| US6522915(B1) | 2003-02-01 | Ceballos et al. | Applicant |
| US6542775(B2) | 2003-04-01 | Ding et al. | Applicant |
| US6553259(B2) | 2003-04-01 | Mouchawar et al. | Applicant |
| US6564106(B2) | 2003-05-01 | Guck et al. | Applicant |
| US6567701(B2) | 2003-05-01 | Vonk | Applicant |
| US6574507(B1) | 2003-06-01 | Bonnet | Applicant |
| US6589188(B1) | 2003-07-01 | Street et al. | Applicant |
| US6595927(B2) | 2003-07-01 | Pitts-Crick | Applicant |
| US6597951(B2) | 2003-07-01 | Kramer et al. | Applicant |
| US6600949(B1) | 2003-07-01 | Turcott | Applicant |
| US6607509(B2) | 2003-08-01 | Bobroff et al. | Applicant |
| US6611712(B2) | 2003-08-01 | Spinelli et al. | Applicant |
| US6615082(B1) | 2003-09-01 | Mandell | Applicant |
| US6615083(B2) | 2003-09-01 | Kupper | Applicant |
| US6615089(B1) | 2003-09-01 | Russie et al. | Applicant |
| US6618619(B1) | 2003-09-01 | Florio et al. | Applicant |
| US6622046(B2) | 2003-09-01 | Fraley et al. | Applicant |
| US6631290(B1) | 2003-10-01 | Guck et al. | Applicant |
| US6640136(B1) | 2003-10-01 | Helland et al. | Applicant |
| US6641542(B2) | 2003-11-01 | Cho et al. | Applicant |
| US6654637(B2) | 2003-11-01 | Rouw et al. | Applicant |
| US6658293(B2) | 2003-12-01 | Vonk | Applicant |
| US6684100(B1) | 2004-01-01 | Sweeney et al. | Applicant |
| US6690967(B2) | 2004-02-01 | Meij | Applicant |
| US6701170(B2) | 2004-03-01 | Stetson | Applicant |
| US6708058(B2) | 2004-03-01 | Kim et al. | Applicant |
| US6725085(B2) | 2004-04-01 | Schwartzman et al. | Applicant |
| US6731973(B2) | 2004-05-01 | Voith | Applicant |
| US6731983(B2) | 2004-05-01 | Ericksen et al. | Applicant |
| US6731984(B2) | 2004-05-01 | Cho et al. | Applicant |
| US6731985(B2) | 2004-05-01 | Bradley et al. | Applicant |
| US6738668(B1) | 2004-05-01 | Mouchawar et al. | Applicant |
| US6738669(B1) | 2004-05-01 | Sloman et al. | Applicant |
| US6754523(B2) | 2004-06-01 | Toole | Applicant |
| US6754528(B2) | 2004-06-01 | Bardy et al. | Applicant |
| US6760615(B2) | 2004-07-01 | Ferek-Petric | Applicant |
| US6766190(B2) | 2004-07-01 | Ferek-Petric | Applicant |
| US6768923(B2) | 2004-07-01 | Ding et al. | Applicant |
| US6768924(B2) | 2004-07-01 | Ding et al. | Applicant |
| US6772008(B2) | 2004-08-01 | Zhu et al. | Applicant |
| US6773404(B2) | 2004-08-01 | Poezevera et al. | Applicant |
| US6778860(B2) | 2004-08-01 | Ostroff et al. | Applicant |
| US6782291(B1) | 2004-08-01 | Bornzin et al. | Applicant |
| US6788974(B2) | 2004-09-01 | Bardy et al. | Applicant |
| US6830548(B2) | 2004-12-01 | Bonnet et al. | Applicant |
| US6834204(B2) | 2004-12-01 | Ostroff et al. | Applicant |
| US6856835(B2) | 2005-02-01 | Bardy et al. | Applicant |
| US6865417(B2) | 2005-03-01 | Rissmann et al. | Applicant |
| US6866044(B2) | 2005-03-01 | Bardy et al. | Applicant |
| US6881192(B1) | 2005-04-01 | Park | Applicant |
| US6884218(B2) | 2005-04-01 | Olson et al. | Applicant |
| US6885893(B1) | 2005-04-01 | Lu | Applicant |
| US6888538(B2) | 2005-05-01 | Ely et al. | Applicant |
| US6889079(B2) | 2005-05-01 | Bocek et al. | Applicant |
| US6890306(B2) | 2005-05-01 | Poezevera | Applicant |
| US6895274(B2) | 2005-05-01 | Mower | Applicant |
| US6904315(B2) | 2005-06-01 | Panken et al. | Applicant |
| US6904320(B2) | 2005-06-01 | Park et al. | Applicant |
| US6915160(B2) | 2005-07-01 | Auricchio et al. | Applicant |
| US6915164(B2) | 2005-07-01 | Bradley et al. | Applicant |
| US6917832(B2) | 2005-07-01 | Hutten et al. | Applicant |
| US6925324(B2) | 2005-08-01 | Shusterman | Applicant |
| US6925330(B2) | 2005-08-01 | Kleine | Applicant |
| US6927721(B2) | 2005-08-01 | Ostroff | Applicant |
| US6928324(B2) | 2005-08-01 | Park et al. | Applicant |
| US6937907(B2) | 2005-08-01 | Bardy et al. | Applicant |
| US6944495(B2) | 2005-09-01 | MacAdam et al. | Applicant |
| US6944579(B2) | 2005-09-01 | Shimizu | Applicant |
| US6950702(B2) | 2005-09-01 | Sweeney | Applicant |
| US6950705(B2) | 2005-09-01 | Bardy et al. | Applicant |
| US6952608(B2) | 2005-10-01 | Ostroff | Applicant |
| US6952610(B2) | 2005-10-01 | Ostroff | Applicant |
| US6954670(B2) | 2005-10-01 | Ostroff | Applicant |
| US6959214(B2) | 2005-10-01 | Pape et al. | Applicant |
| US6961613(B2) | 2005-11-01 | Bjorling et al. | Applicant |
| US6961619(B2) | 2005-11-01 | Casey | Applicant |
| US6973350(B1) | 2005-12-01 | Levine et al. | Applicant |
| US6975904(B1) | 2005-12-01 | Sloman | Applicant |
| US6978178(B2) | 2005-12-01 | Sommer et al. | Applicant |
| US6983264(B2) | 2006-01-01 | Shimizu | Applicant |
| US6988003(B2) | 2006-01-01 | Bardy et al. | Applicant |
| US6993379(B1) | 2006-01-01 | Kroll | Applicant |
| US6993389(B2) | 2006-01-01 | Ding et al. | Applicant |
| US6999817(B2) | 2006-02-01 | Park et al. | Applicant |
| US7006869(B2) | 2006-02-01 | Bradley | Applicant |
| US7025730(B2) | 2006-04-01 | Cho et al. | Applicant |
| US7027861(B2) | 2006-04-01 | Thompson | Applicant |
| US7027868(B2) | 2006-04-01 | Rueter et al. | Applicant |
| US7027871(B2) | 2006-04-01 | Burnes et al. | Applicant |
| US7031773(B1) | 2006-04-01 | Levine et al. | Applicant |
| US7039459(B2) | 2006-05-01 | Bardy | Applicant |
| US7039465(B2) | 2006-05-01 | Bardy | Applicant |
| US7043299(B2) | 2006-05-01 | Erlinger | Applicant |
| US7050851(B2) | 2006-05-01 | Plombon et al. | Applicant |
| US7062327(B2) | 2006-06-01 | Bradley et al. | Applicant |
| US7065400(B2) | 2006-06-01 | Schechter | Applicant |
| US7065407(B2) | 2006-06-01 | Bardy | Applicant |
| US7065410(B2) | 2006-06-01 | Bardy et al. | Applicant |
| US7069080(B2) | 2006-06-01 | Bardy | Applicant |
| US7076296(B2) | 2006-07-01 | Rissmann et al. | Applicant |
| US7079988(B2) | 2006-07-01 | Albera | Applicant |
| US7081095(B2) | 2006-07-01 | Lynn et al. | Applicant |
| US7085599(B2) | 2006-08-01 | Kim et al. | Applicant |
| US7090682(B2) | 2006-08-01 | Sanders et al. | Applicant |
| US7092754(B2) | 2006-08-01 | Bardy et al. | Applicant |
| US7094207(B1) | 2006-08-01 | Koh | Applicant |
| US7096064(B2) | 2006-08-01 | Deno et al. | Applicant |
| US7103404(B2) | 2006-09-01 | Staler et al. | Applicant |
| US7107093(B2) | 2006-09-01 | Burnes | Applicant |
| US7113823(B2) | 2006-09-01 | Yonce et al. | Applicant |
| US7115097(B2) | 2006-10-01 | Johnson | Applicant |
| US7117036(B2) | 2006-10-01 | Florio | Applicant |
| US7120495(B2) | 2006-10-01 | Bardy et al. | Applicant |
| US7123960(B2) | 2006-10-01 | Ding | Applicant |
| US7127290(B2) | 2006-10-01 | Girouard | Applicant |
| US7129935(B2) | 2006-10-01 | Mackey | Applicant |
| US7139610(B2) | 2006-11-01 | Ferek-Petric | Applicant |
| US7144586(B2) | 2006-12-01 | Levy et al. | Applicant |
| US7146212(B2) | 2006-12-01 | Bardy et al. | Applicant |
| US7149575(B2) | 2006-12-01 | Ostroff et al. | Applicant |
| US7155278(B2) | 2006-12-01 | King et al. | Applicant |
| US7160252(B2) | 2007-01-01 | Cho | Applicant |
| US7177689(B2) | 2007-02-01 | Ternes et al. | Applicant |
| US7179229(B1) | 2007-02-01 | Koh | Applicant |
| US7181285(B2) | 2007-02-01 | Lindh | Applicant |
| US7184835(B2) | 2007-02-01 | Kramer et al. | Applicant |
| US7191003(B2) | 2007-03-01 | Greenhut et al. | Applicant |
| US7191004(B2) | 2007-03-01 | Kim et al. | Applicant |
| US7194302(B2) | 2007-03-01 | Bardy et al. | Applicant |
| US7194309(B2) | 2007-03-01 | Ostroff et al. | Applicant |
| US7194313(B2) | 2007-03-01 | Libbus | Applicant |
| US7203540(B2) | 2007-04-01 | Ding et al. | Applicant |
| US7203542(B2) | 2007-04-01 | Obel | Applicant |
| US7203543(B2) | 2007-04-01 | Meyer et al. | Applicant |
| US7212862(B2) | 2007-05-01 | Park et al | Applicant |
| US7225021(B1) | 2007-05-01 | Park et al. | Applicant |
| US7228173(B2) | 2007-06-01 | Cazares | Applicant |
| US7233821(B2) | 2007-06-01 | Hettrick et al. | Applicant |
| US7236819(B2) | 2007-06-01 | Brockway | Applicant |
| US7242978(B2) | 2007-07-01 | Cao | Applicant |
| US7245962(B2) | 2007-07-01 | Ciaccio et al. | Applicant |
| US7248921(B2) | 2007-07-01 | Palreddy et al. | Applicant |
| US7248925(B2) | 2007-07-01 | Bruhns et al. | Applicant |
| US7263399(B2) | 2007-08-01 | Carlson | Applicant |
| US7277754(B2) | 2007-10-01 | McCabe et al. | Applicant |
| US7286876(B2) | 2007-10-01 | Yonce et al. | Applicant |
| US7299086(B2) | 2007-11-01 | McCabe et al. | Applicant |
| US7299093(B2) | 2007-11-01 | Zhu et al. | Applicant |
| US7308311(B2) | 2007-12-01 | Sorensen | Applicant |
| US7319900(B2) | 2008-01-01 | Kim et al. | Applicant |
| US7330761(B2) | 2008-02-01 | Zhang | Applicant |
| US7337000(B2) | 2008-02-01 | Meyer et al. | Applicant |
| US7359749(B2) | 2008-04-01 | Quenet et al. | Applicant |
| US7369889(B2) | 2008-05-01 | Astrom et al. | Applicant |
| US7392086(B2) | 2008-06-01 | Sathaye | Applicant |
| US7426412(B1) | 2008-09-01 | Schecter | Applicant |
| US7438686(B2) | 2008-10-01 | Cho | Applicant |
| US7457664(B2) | 2008-11-01 | Zhang et al. | Applicant |
| US7463924(B2) | 2008-12-01 | Bardy et al. | Applicant |
| US7468040(B2) | 2008-12-01 | Hartley | Applicant |
| US7477932(B2) | 2009-01-01 | Lee | Applicant |
| US7499751(B2) | 2009-03-01 | Meyer et al. | Applicant |
| US7509170(B2) | 2009-03-01 | Zhang et al. | Applicant |
| US7519423(B2) | 2009-04-01 | Begemann et al. | Applicant |
| US7558628(B2) | 2009-07-01 | Yonce et al. | Applicant |
| US7580741(B2) | 2009-08-01 | Cazares et al. | Applicant |
| US7587240(B2) | 2009-09-01 | Zhang et al. | Applicant |
| US7617002(B2) | 2009-11-01 | Goetz | Applicant |
| US7647108(B2) | 2010-01-01 | Freeberg | Applicant |
| US7653431(B2) | 2010-01-01 | Cazares et al. | Applicant |
| US7680536(B2) | 2010-03-01 | Sathaye et al. | Applicant |
| US7684861(B2) | 2010-03-01 | Sanders | Applicant |
| US7706866(B2) | 2010-04-01 | Zhang et al. | Applicant |
| US7734347(B2) | 2010-06-01 | Sathaye et al. | Applicant |
| US7738959(B2) | 2010-06-01 | Manrodt et al. | Applicant |
| US7761162(B2) | 2010-07-01 | Dong et al. | Applicant |
| US2002/0002327(A1) | 2002-01-01 | Grant et al. | Applicant |
| US2002/0035377(A1) | 2002-03-01 | Bardy et al. | Applicant |
| US2002/0035378(A1) | 2002-03-01 | Bardy et al. | Applicant |
| US2002/0035379(A1) | 2002-03-01 | Bardy et al. | Applicant |
| US2002/0035381(A1) | 2002-03-01 | Bardy et al. | Applicant |
| US2002/0052631(A1) | 2002-05-01 | Sullivan et al. | Examiner |
| US2002/0082658(A1) | 2002-06-01 | Heinrich et al. | Applicant |
| US2002/0095184(A1) | 2002-07-01 | Bardy et al. | Applicant |
| US2002/0107544(A1) | 2002-08-01 | Ostroff et al. | Applicant |
| US2002/0107545(A1) | 2002-08-01 | Rissmann et al. | Applicant |
| US2002/0143264(A1) | 2002-10-01 | Ding et al. | Applicant |
| US2003/0023175(A1) | 2003-01-01 | Arzbaecher et al. | Applicant |
| US2003/0083708(A1) | 2003-05-01 | Bradley et al. | Applicant |
| US2003/0135248(A1) | 2003-07-01 | Stypulkowski | Examiner |
| US2003/0195571(A1) | 2003-10-01 | Burnes et al. | Applicant |
| US2003/0199945(A1) | 2003-10-01 | Ciulla | Applicant |
| US2003/0204213(A1) | 2003-10-01 | Jensen et al. | Applicant |
| US2003/0212436(A1) | 2003-11-01 | Brown | Applicant |
| US2004/0064162(A1) | 2004-04-01 | Manrodt et al. | Applicant |
| US2004/0082975(A1) | 2004-04-01 | Meyer et al. | Applicant |
| US2004/0116971(A1) | 2004-06-01 | Bjorling et al. | Applicant |
| US2004/0116978(A1) | 2004-06-01 | Bradley | Examiner |
| US2004/0133248(A1) | 2004-07-01 | Frei et al. | Examiner |
| US2004/0172065(A1) | 2004-09-01 | Sih et al. | Applicant |
| US2004/0215253(A1) | 2004-10-01 | Weinberg | Applicant |
| US2004/0215277(A1) | 2004-10-01 | Oosterhoff et al. | Applicant |
| US2004/0230229(A1) | 2004-11-01 | Lovett et al. | Applicant |
| US2004/0260351(A1) | 2004-12-01 | Holmstrom et al. | Applicant |
| US2005/0004612(A1) | 2005-01-01 | Scholten et al. | Applicant |
| US2005/0010120(A1) | 2005-01-01 | Jung | Applicant |
| US2005/0038478(A1) | 2005-02-01 | Klepfer et al. | Applicant |
| US2005/0043652(A1) | 2005-02-01 | Lovett et al. | Applicant |
| US2005/0060002(A1) | 2005-03-01 | Zhu et al. | Applicant |
| US2005/0060007(A1) | 2005-03-01 | Goetz | Applicant |
| US2005/0065587(A1) | 2005-03-01 | Gryzwa | Applicant |
| US2005/0085865(A1) | 2005-04-01 | Tehrani | Applicant |
| US2005/0113710(A1) | 2005-05-01 | Stahmann et al. | Applicant |
| US2005/0131477(A1) | 2005-06-01 | Meyer et al. | Applicant |
| US2005/0131478(A1) | 2005-06-01 | Kim et al. | Applicant |
| US2005/0143785(A1) | 2005-06-01 | Libbus | Applicant |
| US2006/0069322(A1) | 2006-03-01 | Zhang et al. | Applicant |
| US2006/0074331(A1) | 2006-04-01 | Kim et al. | Applicant |
| US2006/0111747(A1) | 2006-05-01 | Cazares et al. | Applicant |
| US2006/0116593(A1) | 2006-06-01 | Zhang et al. | Applicant |
| US2006/0129193(A1) | 2006-06-01 | Zhang | Applicant |
| US2006/0129194(A1) | 2006-06-01 | Zhang | Applicant |
| US2006/0129195(A1) | 2006-06-01 | Sathaye et al. | Applicant |
| US2006/0129196(A1) | 2006-06-01 | Dong et al. | Applicant |
| US2006/0129197(A1) | 2006-06-01 | Zhang et al. | Applicant |
| US2006/0129198(A1) | 2006-06-01 | Zhang et al. | Applicant |
| US2006/0129199(A1) | 2006-06-01 | Zhang et al. | Applicant |
| US2006/0241711(A1) | 2006-10-01 | Sathaye | Examiner |
| US2006/0247693(A1) | 2006-11-01 | Dong | Applicant |
| US2006/0247695(A1) | 2006-11-01 | Stalsberg et al. | Applicant |
| US2006/0253043(A1) | 2006-11-01 | Zhang et al. | Applicant |
| US2006/0253044(A1) | 2006-11-01 | Zhang et al. | Applicant |
| US2007/0049974(A1) | 2007-03-01 | Li et al. | Applicant |
| US2007/0055124(A1) | 2007-03-01 | Viswanathan et al. | Applicant |
| US2007/0142741(A1) | 2007-06-01 | Berthon-Jones et al. | Applicant |
| US2007/0239057(A1) | 2007-10-01 | Pu et al. | Applicant |
| US2007/0255321(A1) | 2007-11-01 | Gerber et al. | Applicant |
| US2008/0004665(A1) | 2008-01-01 | McCabe et al. | Applicant |
| US2008/0009909(A1) | 2008-01-01 | Sathaye et al. | Applicant |
| US2008/0046019(A1) | 2008-02-01 | Sathaye et al. | Applicant |
| US2008/0071318(A1) | 2008-03-01 | Brooke et al. | Applicant |
| US2008/0234556(A1) | 2008-09-01 | Brooke et al. | Applicant |
| US2008/0275522(A1) | 2008-11-01 | Dong | Applicant |
| US2008/0294215(A1) | 2008-11-01 | Sathaye | Applicant |
| US2008/0300644(A1) | 2008-12-01 | Sathaye | Applicant |
| US2009/0030470(A1) | 2009-01-01 | Holmstrom et al. | Examiner |
| US2009/0043351(A1) | 2009-02-01 | Sathaye | Applicant |
| US2009/0043352(A1) | 2009-02-01 | Brooke et al. | Applicant |
| EP468720 | 1992-01-01 | Applicant | |
| EP560569 | 1993-09-01 | Applicant | |
| EP940155 | 1999-09-01 | Applicant | |
| EP1038498 | 2000-09-01 | Applicant | |
| EP1151718 | 2001-11-01 | Applicant | |
| EP1291038 | 2003-03-01 | Applicant | |
| EP1629863 | 2006-03-01 | Applicant | |
| WO9217240 | 1992-10-01 | Applicant | |
| WO9220402 | 1992-11-01 | Applicant | |
| WO9904841 | 1999-04-01 | Applicant | |
| WO1438 | 2000-01-01 | Applicant | |
| WO17615 | 2000-03-01 | Applicant | |
| WO240097 | 2002-05-01 | Applicant | |
| WO247761 | 2002-06-01 | Applicant | |
| WO2087696 | 2002-11-01 | Applicant | |
| WO3003905 | 2003-01-01 | Applicant | |
| WO3028550 | 2003-04-01 | Applicant | |
| WO2004026398 | 2004-04-01 | Applicant | |
| WO2004091720 | 2004-10-01 | Applicant | |
| WO2005058412 | 2005-06-01 | Applicant | |
| WO2005089865 | 2005-09-01 | Applicant | |
| WO2006065707 | 2006-06-01 | Applicant | |
| WO2007087025 | 2007-08-01 | Applicant | |
| WO2008005270 | 2008-01-01 | Applicant | |
| WO2009020639 | 2009-02-01 | Applicant |
Non-Patent Literature (61)
- U.S. Appl. No. 10/955,393, filed Sep. 30, 2004, Freeberg.Applicant
- U.S. Appl. No. 11/114,569, filed Apr. 26, 2005, Sathaye.Applicant
- U.S. Appl. No. 11/890,668, filed Aug. 7, 2007, Sathaye et al.Applicant
- Splett et al. “Determination of Pacing Capture in Implantable Defibrillators: Benefit of Evoked Response Detection Using RV Coil to Can Vector,” PACE, vol. 23, pp. 1645-1650.Applicant
- Acar et al., SVD-based on-line exercise ECG signal orthogonalization, IEEE Transactions on Biomedical Engineering, vol. 46, No. 3, Mar. 1999. Abstract only.Applicant
- Ajilore et al., Nightcap: Laboratory and home-based evaluation of a portable sleep monitor, 32 Psychophysiology, 32-98, 1995. Abstract only.Applicant
- Belouchrani et al., Blind Source Separation Based on Time-Frequency Signal Representations, IEEE Transactions on Signal Processing, vol. 46, No. 11, pp. 2888-2897, Nov. 1998.Applicant
- Cohen et al. Capture Management Efficacy in children and young adults with endocardial and unipolar epicardial systems. Europace, vol. 6, pp. 248-255, 2004.Applicant
- Comon, Independent component analysis, a new concept?, Signal Processing, vol. 36, No. 3, pp. 287-314, Apr. 1994.Applicant
- Gallois et al., Multi-Channel Analysis of the EEG Signals and Statistic Particularities for Epileptic Seizure Forecast, Second Joint EMBS/BMES Conference, pp. 208-215, Oct. 23-26, 2002.Applicant
- Gradaus et al., Nonthoracotomy Implantable Cardioverter Defibrillator Placement in Children: Use of a Subcutaneous Array Leads and Abdominally Placed Implantable Cardioverter Defibrillators in Children, Journal of Cardiovascular Electrophysiology, vol. 12, No. 3, pp. 356-360, Mar. 2001.Applicant
- Hartz et al., New Approach to Defibrillator Insertion, Journal of Thoracic Cardiovascular Surgery, vol. 97, pp. 920-922, 1989.Applicant
- Hyvärinen et al., Independent Component Analysis: A Tutorial, Helsinski University of Technology, Apr. 1999.Applicant
- Kolettis et al., Submammary Implantation of a Cardioverter-Defibrillator with a Nonthoractomy Lead System, American Heart Journal, vol. 126, pp. 1222-1223, Nov. 1993.Applicant
- Krahn et al., Recurrent syncope. Experience with an implantable loop record, Cardiol. Clin., vol. 15(2), pp. 316-326, May 1997.Applicant
- Leng et al., “Lead Configuration for Defibrillator Implantation in a Patient with Congenital Heart Disease and a Mechanical Prosthetic Tricuspid Valve”, PACE, vol. 24, No. 8, pp. 1291-1292, Aug. 2001.Applicant
- Park et al., Use of an Implantable Cardioverter Defibrillator in an Eight-Month-Old Infant with Ventricular Fibrillation Arising from a Myocardial Fibroma, PACE, vol. 22, No. 1, pp. 138-139, Jan. 1999.Applicant
- Rieta, et al., Atrial Activity Extraction Based on Blind Source Separation as an Alternative to QRST Cancellation for Atrial Fibrillation Analysis, Computers in Cardiology, vol. 27, pp. 69-72, 2000.Applicant
- Schuder et al., Experimental Ventricular Defibrillation with an Automatic and Completely Implanted System, Trans. American Society Artif. Int. Organs, vol. 16, pp. 207-212, 1970.Applicant
- Schuder et al., Transthoracic Ventricular Defibrillation in the Dog with Truncated and Untruncated Exponential Stimuli, IEEE Transitions on Bio-Medical Engineering, vol. BME-18, No. 6, pp. 410-415, Nov. 1971.Applicant
- Schuder et al., Ventricular Defibrillation in the Dog Using Implanted and Partially Implanted Electrode Systems, American Journal of Cardiology, vol. 33, pp. 243-247, Feb. 1974.Applicant
- Smits et al., Defibrillation Threshold (DFT) Model of a Fully Subcutaneous ICD System, Europace Supplements, vol. 2, Jun. 2001 at column 778, p. B83.Applicant
- Stirbis et al., Optimizing of the Shape of Implanted Artificial Pacemakers, Kaunas Medical Institute, Translated from Meditsinskaya Tekhnika, No. 6, pp. 25-27, 1986.Applicant
- Verrier et al., Sleep, dreams, and sudden death: the case for sleep as an autonomic stress test for the heart, 31 Cardiovascular Research 181-211, 1996.Applicant
- Verrier et al., Sleep Related Cardiovascular Risk: New Home-Based Monitoring Technology for Improved Diagnosis and Therapy, 2 A.N.E. 158-175, 1997.Applicant
- Waldemark et al., Detection of Apnea using Short Window FFT Technique and Artificial Neural Network, 3390 SPIE International Society for Optical Engineering 122-133, 1998. Partial article.Applicant
- Zarzoso et al., Blind Separation of Independent Sources for Virtually Any Source Probability Density Function, IEEE Transactions on Signal Processing, vol. 47, No. 9, pp. 2419-2432, Sep. 1999.Applicant
- Zarzoso et al., Noninvasive Fetal Electrocardiogram Extraction: Blind Separation Versus Adaptive Noise Cancellation, IEEE Transactions on Biomedical Engineering, vol. 48, No. 1, pp. 12-18, Jan. 2001.Applicant
- Office Action dated Apr. 17, 2007 from U.S. Appl. No. 11/114,569, 11 pages.Applicant
- Office Action Response dated Aug. 17, 2007 from U.S. Appl. No. 11/114,569, 9 pages.Applicant
- Office Action dated Nov. 14, 2007 from U.S. Appl. No. 11/114,569, 13 pages.Applicant
- Office Action Response dated Jan. 14, 2008 from U.S. Application No. 11/114,569, 8 pages.Applicant
- Notice of Allowance dated Feb. 14, 2008 from U.S. Appl. No. 11/114,569, 4 pages.Applicant
- Office Action dated Nov. 9, 2007 from U.S. Appl. No. 10/955,393, 13 pages.Applicant
- Office Action Response dated Apr. 21, 2008 from U.S. Appl. No. 10/955,393, 12 pages.Applicant
- Office Action dated Jul. 31, 2008 from U.S. Appl. No. 10/955,393, 8 pages.Applicant
- Office Action Response dated Dec. 22, 2008 from U.S. Appl. No. 10/955,393, 9 pages.Applicant
- Office Action dated Mar. 20, 2009 from U.S. Appl. No. 10/955,393, 10 pages.Applicant
- Office Action Response dated Jun. 9, 2009 from U.S. Appl. No. 10/955,393, 10 pages.Applicant
- Notice of Allowance dated Sep. 2, 2009 from U.S. Appl. No. 10/955,393, 4 pages.Applicant
- Office Action dated Mar. 28, 2007 from U.S. Appl. No. 11/116,558, 13 pages.Applicant
- Office Action Response dated Sep. 28, 2007 from U.S. Appl. No. 11/116,558, 15 pages.Applicant
- Office Action Response dated Oct. 29, 2007 from U.S. Appl. No. 11/116,558, 7 pages.Applicant
- Office Action dated Mar. 6, 2008 from U.S. Appl. No. 11/116,558, 14 pages.Applicant
- Office Action Response dated May 6, 2008 from U.S. Appl. No. 11/116,558, 11 pages.Applicant
- Office Action dated May 28, 2008 from U.S. Appl. No. 11/116,558, 3 pages.Applicant
- International Search Report and Written Opinion dated Dec. 12, 2008 from PCT Application No. PCT/US2008/009488, 14 pages.Applicant
- International Preliminary Report on Patentability dated Feb. 18, 2010 from PCT Application No. PCT/US2008/009488, 7 pages.Applicant
- International Search Report and Written Opinion dated Apr. 6, 2009 from PCT Application No. PCT/US2009/033687, 16 pages.Applicant
- File history from Sep. 1, 2010-Oct. 31, 2010 for U.S. Appl. No. 11/890,668 retrieved from USPTO System on Nov. 1, 2010, 19 pages.Applicant
- File history for U.S. Appl. No. 11/890,668 as retrieved from U.S. Patent and Trademark System on Jan. 21, 2011, 234 pages.Applicant
- File history for U.S. Appl. No. 12/154,410 as retrieved from U.S. Patent and Trademark System on Dec. 28, 2011, 213 pages.Applicant
- File history for U.S. Appl. No. 12/154,411 as retrieved from U.S. Patent and Trademark Office Pair System on Dec. 28, 2011, 181 pages.Applicant
- File history for U.S. Appl. No. 11/890,668 as retrieved from U.S. Patent and Trademark System on Dec. 28, 2011, 337 pages.Applicant
- File history for U.S. Appl. No. 12/217,652 as retrieved from U.S. Patent and Trademark System on Dec. 28, 2011, 191 pages.Applicant
- File history for U.S. Appl. No. 12/220,496 as retrieved from U.S. Patent and Trademark System on Dec. 28, 2011, 221 pages.Applicant
- File history for U.S. Appl. No. 12/368,828 as retrieved from U.S. Patent and Trademark System on Dec. 28, 2011, 191 pages.Applicant
- File history for U.S. Appl. No. 11/890,668 as retrieved from U.S. Patent and Trademark System on Jul. 18, 2011, 269 pages.Applicant
- File history for U.S. Appl. No. 12/217,652 as retrieved from U.S. Patent and Trademark System on Jul. 18, 2011, 154 pages.Applicant
- File history for EP Application No. 08795112.5 as retrieved from the European Patent Office electronic file system on Jul. 18, 2011, 140 pages.Applicant
- Office Action dated May 13, 2011 from Australian Application No. 2008284265, 3 pages.Applicant